Market news
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), today announced that members of its executive leadership team will present at and participate in the H.C. Wainwright 28th Annual Global Investment Conference, being held September 14–16 in New York City. Genprex is a clinical-stage biotechnology company developing gene therapies designed to restore tumor-suppressor function in cancer and insulin-producing function in diabetes. The Company's lead oncology program is in clinical developmen
Andelyn Biosciences, a leading contract development and manufacturing organization, announced today that Genprex, Inc. has selected Andelyn to support scale-up manufacturing for its diabetes gene therapy program.
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it has entered into a development and manufacturing agreement with a leading U.S. based clinical and commercial Contract Development and Manufacturing Organization (CDMO) to initiate the manufacturing scale-up of its diabetes gene therapy program. This strategic selection allows for the transitio
Detailed price information for Genprex Inc (GNPX-Q) from The Globe and Mail including charting and trades.
Validation studies are expected to conclude by the end of 2026, with potential integration into the NSCLC clinical programme thereafter.
Genprex Inc. (NASDAQ:GNPX) shares gained 3% on Monday after the clinical-stage biotechnology company announced a collaboration with Roche Diagnostics to validate biomarkers designed to improve patient selection in clinical trials for non-small cell lung cancer (NSCLC).
Detailed price information for Genprex Inc (GNPX-Q) from The Globe and Mail including charting and trades.
Detailed price information for Genprex Inc (GNPX-Q) from The Globe and Mail including charting and trades.
This is the newest page. Registered accounts read further back.